Zobrazeno 1 - 10 of 46 pro vyhledávání: '"Neeraja Idamakanti"'
3
Data from Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice
Autor: Karin Jooss, Chae-Ok Yun, Michael Robinson, Melinda VanRoey, Marina Abramova, Neeraja Idamakanti, Melissa Gonzalez Edick, Shanthi Ganesh
Selective replication of oncolytic viruses in tumor cells provides a promising approach for the treatment of human cancers. One of the limitations observed with oncolytic viruses currently used in the treatment of solid tumors is the inefficient spre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d1f265ea6de98bcabbeffe10a742e5
https://doi.org/10.1158/0008-5472.c.6496427.v1
Zobrazit plný text záznamu
4
Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models
Autor: Dean F. Rigel, Hidetomo Imase, Kayo Yasoshima, Darcy Kohls, Toshio Kawanami, Yukiko I. Yagi, Jun Yuan, Monish Jain, Hyi-Man Park, Upendra A. Argikar, David Yowe, Paul Taslimi, Xiaoling Xie, Yuki Iwaki, Neeraja Idamakanti, Taeyong Yoon, Ken Yamada, Vidya Kunjathoor, Keith DiPetrillo, Lingfei Xu, Mitsunori Kato, Meicheng Zhu, Julian Levell, Zachary Robinson, Lauren G. Monovich
Publikováno v: Journal of Medicinal Chemistry. 60:7099-7107
The observed structure-activity relationship of three distinct ATP noncompetitive With-No-Lysine (WNK) kinase inhibitor series, together with a crystal structure of a previously disclosed allosteric inhibitor bound to WNK1, led to an overlay hypothes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3d52943277800bc7194904670e9e1d7
https://doi.org/10.1021/acs.jmedchem.7b00708
Zobrazit plný text záznamu
5
A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys
Autor: Glennda Smithson, Jonathan Zalevsky, Cindy Q. Xia, Mary Carsillo, Neeraja Idamakanti, Pu Shi, Josh Yuan, Wouter Korver, Matthew Wagoner, Eric R. Fedyk, Lachy McLean
Publikováno v: The Journal of pharmacology and experimental therapeutics. 370(2)
Ectoenzyme CD38 is increased on lymphocytes in response to an antigenic challenge and it9s hypothesized that targeting these activated lymphocytes could ameliorate pathologic activities in autoimmune diseases. The cynomolgus monkey is an appropriate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3f0b56a867c281f2844a5dd64685df
https://pubmed.ncbi.nlm.nih.gov/31085699
Zobrazit plný text záznamu
6
Discovery and Characterization of Allosteric WNK Kinase Inhibitors
Autor: Mitsunori Kato, Jason Gunawan, Xiaoling Xie, Muneto Mogi, Neeraja Idamakanti, Waan-Jeng Huang, Daniel LaSala, Ken Yamada, Hajime Yoshisue, Hyi-Man Park, Zhan Deng, Darcy Kohls, Yukiko I. Yagi, David Yowe, Kayo Yasoshima, Amy Qiongshu Xie, Reinhardt Juergen, Debra Burdick, Natasha Kreder, Q. Kimberley Yue, Pramod Pandey, Peter Drueckes, Isabel Schmidt, Toshio Kawanami, Hiromichi Wakai, Ji-Hu Zhang
Publikováno v: ACS Chemical Biology. 11:3338-3346
Protein kinases are known for their highly conserved adenosine triphosphate (ATP)-binding site, rendering the discovery of selective inhibitors a major challenge. In theory, allosteric inhibitors can achieve high selectivity by targeting less conserv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b363e34512a8c7147a1bb8f1b5e7f58f
https://doi.org/10.1021/acschembio.6b00511
Zobrazit plný text záznamu
7
The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells
Autor: Jose Estevam, Gezim Lahu, Mary Carsillo, Matthew Wagoner, Vivian Hernandez, Eric R. Fedyk, Jia Chen, Kristina Allikmets, Deborah Berg, Neeraja Idamakanti, Antonio Palumbo
Publikováno v: Blood. 134:3136-3136
Introduction: The CD38 antigen is a target for treating multiple myeloma and is being investigated for disorders caused by plasma cells. Therapeutics bind to CD38 on red blood cells and platelets in the vasculature, prior to myeloma and plasma cells
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ffb0b7c5cf768030910c4c24f15b895
https://doi.org/10.1182/blood-2019-128238
Zobrazit plný text záznamu
8
Abstract 3252: TAK-981: A first in class SUMO inhibitor in Phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell priming
Autor: Kristina Xega, Xingyue He, Neeraja Idamakanti, Mithun Khattar, Stephen Grossman, Keli Song, Dennis Huszar
Publikováno v: Cancer Research. 79:3252-3252
SUMOylation is a reversible post-translational modification that regulates protein function by covalent attachment of the small ubiquitin-like modifier (SUMO) protein to protein substrates. TAK-981 is a novel, selective small molecule inhibitor of th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c319881b888e61ba7f0bada44c1a716
https://doi.org/10.1158/1538-7445.am2019-3252
Zobrazit plný text záznamu
9
Abstract 1523: Inhibition of SUMOylation by TAK-981 induces antitumor innate immune responses by modulating macrophage and NK cell function through Type I IFN pathway activation
Autor: Akito Nakamura, Stephen Grossman, Keli Song, Neeraja Idamakanti, Gary Shapiro, Dennis Huszar
Publikováno v: Cancer Research. 79:1523-1523
TAK-981 is a novel and selective small molecule inhibitor of the small ubiquitin-like modifier (SUMO) ylation enzymatic cascade in Phase 1 clinical trials. SUMOylation is a reversible post-translational modification that regulates protein function by
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d1f03aaefaf3a6aae41174bc759014f2
https://doi.org/10.1158/1538-7445.am2019-1523
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje